Iaso Bio

Executive Summary

Iaso Bio is a clinical-stage biotechnology company pioneering engineered regulatory T-cell (Treg) therapies to restore immune tolerance in autoimmune and inflammatory diseases. Founded in 2021 and headquartered in San Diego, the company has raised $74.1M to advance its platform. Its lead candidate, IASO-782, is an autologous CD8+ Treg therapy currently in a Phase 1b trial for systemic lupus erythematosus (SLE). By leveraging the immunosuppressive properties of Tregs, Iaso Bio aims to address the underlying cause of autoimmunity rather than just managing symptoms, potentially offering a transformative treatment paradigm. The company's approach is innovative but early-stage, with competition from other cell therapy developers and conventional biologics. Key risks include manufacturing complexity, safety and efficacy data, and the need for additional financing to progress through clinical development. A successful Phase 1b readout could de-risk the platform and attract partnership or funding opportunities. Iaso Bio represents a high-risk, high-reward investment in the burgeoning field of cell therapy for autoimmune diseases, with near-term catalysts centered on clinical data milestones and capital raises.

Upcoming Catalysts (preview)

• Q4 2026Phase 1b interim data for IASO-782 in SLE70% success
• Q2 2027Initiation of Phase 2 trial for IASO-78260% success
• Q3 2026Series B financing or major partnership50% success